Venn Life Sciences Grows CRO Business in Europe
Venn Life Sciences, a CRO providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the recent acquisition of two European CROs.
Venn Life Sciences, a CRO providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the recent acquisition of two European CROs. Venn acquired German CRO CRM clinical trials and Medevol Clinical Services in the UK. Venn has operations in France, Ireland, the Netherlands, Russia, the UK and a branch office in Switzerland. It also has a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe.
Founded in 1996, CRM is a full-service CRO based in Rheinbach, Germany, specializing in Phases II-IV. CRM has extensive experience in dermatology, pneumology and urology, and its suite of services include initial and ongoing training for study nurses, investigators and trial teams in the areas of quality, planning andmonitoring of clinical studies.
The second acquisition is Medevol, a CRO in the UK clinical trials market since 2001, conducting full-service studies for global pharmaceutical and biotechnology companies across Phases II - IV. With extensive therapeutic experience across a broad range of indications, Medevol also provide contract staffing solutions. The company is based in Belfast.
You can read the full release here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
